Trials / Active Not Recruiting
Active Not RecruitingNCT06858839
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 3,853 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Maridebart Cafraglutide | Maridebart cafraglutide will be administered SC. |
| DRUG | Placebo | Placebo will be administered SC. |
Timeline
- Start date
- 2025-03-12
- Primary completion
- 2027-01-21
- Completion
- 2027-04-16
- First posted
- 2025-03-05
- Last updated
- 2025-10-20
Locations
243 sites across 17 countries: United States, Argentina, Australia, Belgium, Canada, Czechia, Denmark, Finland, Germany, Italy, Japan, Poland, Puerto Rico, South Korea, Spain, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06858839. Inclusion in this directory is not an endorsement.